| Literature DB >> 23008807 |
Deval B Patel1, Falgun A Mehta, Kashyap K Bhatt.
Abstract
An isocratic reversed-phase liquid chromatograpic assay method was developed for the quantitative determination of amlodipine besylate (AML) and indapamide (IND) in combined dosage form. A Brownlee C-18, 5 μm column with a mobile phase containing 0.02 M potassium dihydrogen phosphate-methanol (30+70, v/v) total pH-adjusted to 3 using o-phosphoric acid was used. The flow rate was 1.0 mL min(-1) and effluents were monitored at 242 nm. The retention times of amlodipine besylate and indapamide were 5.9 min and 3.6 min, respectively. The proposed method was validated with respect to linearity, accuracy, precision, and robustness. The method was successfully applied to the estimation of amlodipine besylate and indapamide in combined tablet dosage forms.Entities:
Keywords: Amlodipine; Indapamide; RP-HPLC; Tablet; Validation
Year: 2012 PMID: 23008807 PMCID: PMC3447622 DOI: 10.3797/scipharm.1203-07
Source DB: PubMed Journal: Sci Pharm ISSN: 0036-8709
Fig. 2HPLC chromatogram of IND (RT 3.6 min) and AML (RT 5.9 min), using 0.02 M KH2PO4-methanol (30+70, v/v) total pH adjusted to 3 using O-phosphoric acid as mobile phase
System suitability test parameters for AML and IND at the proposed HPLC method
| Parameters | AML | IND |
|---|---|---|
| Retention time (min) | 5.6 | 3.9 |
| Asymmetry | 1.36 | 1.27 |
| Resolution | 2.0 | |
| Theoretical Plates | 4222 | 4322 |
Data derived from accuracy study of the proposed method
| Drug | Level | Amount taken (μg/ml) | Amount added (μg/ml) | Amount found (μg/ml) | % Recovery | RSD (n = 5) |
|---|---|---|---|---|---|---|
| AML | 0% | 5 | – | 5.08 | 101.6 | 1.65 |
| 50 % | 5 | 2.5 | 7.46 | 99.46 | 0.83 | |
| 100 % | 5 | 5 | 9.96 | 99.6 | 1.96 | |
| 150 % | 5 | 7.5 | 12.45 | 99.6 | 1.79 | |
|
| ||||||
| IND | 0% | 1.5 | – | 1.45 | 97.33 | 1.43 |
| 50 % | 1.5 | 0.75 | 2.29 | 100.88 | 1.02 | |
| 100 % | 1.5 | 1.5 | 2.97 | 99 | 1.82 | |
| 150 % | 1.5 | 2.25 | 3.72 | 99.2 | 0.64 | |
Robustness Studies
| Method parameter/Condition | Deliberate changes | RSD of peak area (n=5) | |
|---|---|---|---|
|
| |||
| AML | IND | ||
| Flow rate | 0.8 ml/min | 0.49 | 0.33 |
| 1.2 ml/min | 0.54 | 0.67 | |
|
| |||
| Mobile phase ratio 0.02 M KH2PO4:Methanol (total pH adjusted to 3 using | 20:80(V/V) | 0.48 | 0.75 |
| 40:60(V/V) | 0.84 | 1.10 | |
Regression analysis of calibration curves
| Parameters | AML | IND |
|---|---|---|
| Range | 0.25–35 (μg/ml) | 0.075–10.5 (μg/ml) |
| Slope | 37607 | 85909 |
| SD of slope | 101.25 | 739.78 |
| Intercept | 39026 | 33014 |
| SD of intercept | 33094.16 | 25772.7 |
| Corr. Coefficient | 0.9951 | 0.9945 |
Summary of validation and system suitability parameters
| Parameters | AML | IND |
|---|---|---|
| Retention time (min) | 5.6 | 3.9 |
| Asymmetry | 1.36 | 1.27 |
| Resolution | 2.0 | |
| Theoretical Plates | 4222 | 4322 |
| Detection limit (ng/ml) | 2.9 | 0.99 |
| Quantitation limit (ng/ml) | 8.8 | 3 |
| Accuracy(%) | 99.46–101.60 | 99.46–01.60 |
| Precision (%RSD) | ||
| Intra-day (n=3) | 1.23–1.78 | 1.06–1.86 |
| Inter-day (n=3) | 1.02–1.53 | 0.90–1.26 |
| Instrument precision (%RSD) | 0.18–0.63% | 0.61–0.79%, |
| Robustness | robust | |
| Specificity | specific | |
Assay results of marketed formulation
| Tablet Brand | Amount taken (μg/ml) | Amount found (μg/ml) | % Assay ± S.D. (n =5) | |||
|---|---|---|---|---|---|---|
|
| ||||||
| AML | IND | AML | IND | AML | IND | |
| Amlodac-D | 5 | 1.5 | 4.93 | 1.49 | 98.6 ± 1.55 | 99.3 ± 1.74 |
| NAITRILAM | 5 | 1.5 | 5.09 | 1.47 | 101.8 ± 1.65 | 98.0 ± 1.21 |